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Lung cancer is the leading cause of cancer deaths worldwide. microRNAs (miRNAs) are a
class of small non-coding RNA species that have been implicated in the control of many
fundamental cellular and physiological processes such as cellular differentiation, prolifer-
ation, apoptosis, and stem cell maintenance. Some miRNAs have been categorized as
“oncomiRs” as opposed to “tumor suppressor miRs.” This review focuses on the role of
miRNAs in the lung cancer carcinogenesis and their potential as diagnostic, prognostic, or
predictive markers.
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INTRODUCTION
Lung cancer is the most common invasive cancer and cause of
cancer death worldwide (Ferlay et al., 2010). Among lung cancers,
80% are classified as non-small cell lung cancer (NSCLC) and 20%
are small cell lung cancer (SCLC). While recent developments in
computed tomography (CT) screening for NSCLC may lead to
detection of tumors at earlier stages (Aberle et al., 2011a), currently
over 70% of lung cancers are loco-regionally advanced or metasta-
tic at the time of diagnosis. Despite advances in chemotherapy,
radiotherapy, and surgery the death rate from lung cancer has
remained largely unchanged. In recent years therapeutic decisions
in NSCLC have been more and more based on histological and
molecular characteristics. The era of molecular targeted therapy
in lung cancer had its origin in 2004, when activating mutations in
the epidermal growth factor receptor (EGFR) and their correlation
with clinical response to EGFR tyrosine kinase inhibitors (TKIs)
were discovered (Lynch et al., 2004; Paez et al., 2004; Pao et al.,
2004). Other oncogenic drivers in lung adenocarcinoma include
mutations of BRAF, NRAS, KRAS, MET, PIK3CA, HER2, RET,
JAK2, ROS1, and ALK (Bronte et al., 2010; Garber, 2010; Janku
et al., 2010; Pao and Girard, 2011). Although most of the patients
with advanced NSCLC do not harbor one of the mentioned molec-
ular alterations. Therefore, it is important to identify new markers
for molecularly targeted therapy.
The most studied epigenetic phenomena include posttransla-
tional modifications in DNA and histone proteins. In the recent
years the changes in expression levels of small, non-coding, single-
stranded RNAs – so called microRNAs (miRNAs) – have been
detected and described. miRNAs are usually 18–25 nucleotides
long. Depending on the degree of homology to their 3′UTR target
sequence, miRNAs induce translational repression or degradation
of mRNAs (Figure 1). It is estimated that more than 1,000 miR-
NAs are transcribed and that 30% of the human genome is under
miRNA regulation, one miRNA being able to modulate post-
transcriptionally hundreds of downstream genes. In this regard,
miRNAs control a wide range of biological processes including
cellular differentiation, proliferation, apoptosis, and stem cell
maintenance. More than half of the miRNAs genes are located
in cancer-associated genomic regions or in fragile sites. Several
miRNAs located in deleted regions have low expression levels in
cancer tissues (Calin et al., 2004). miRNAs can act as tumor sup-
pressors when their function loss can initiate or contribute to the
malignant transformation of a normal cell. The loss of function of
a miRNA could be due to several mechanisms, including genomic
deletion, mutation, epigenetic silencing, and/or miRNA process-
ing alterations (Calin et al., 2002, 2005; Saito et al., 2006; Nakamura
et al., 2007). On the other hand miRNAs can act as oncogenes.
In this review the focus will be on the state-of-the-art knowl-
edge currently available on the clinical significance of miRNAs in
lung carcinogenesis and their role as diagnostic, prognostic, and
predictive markers in lung cancer.
MicroRNAs AND LUNG CARCINOGENESIS
Several studies have identified an important role of miRNAs in the
regulation of the cell cycle and carcinogenesis in different organs,
including the lung (Carleton et al., 2007; Chivukula and Mendell,
2008). The first evidence of miRNA deregulation in lung cancer
came from the study by Volinia et al. (2006), who identified a group
of miRNAs frequently aberrantly expressed in tumor tissues with
respect to the normal tissue counterpart. Takahashi et al. (2009)
found decreased expression of miR-107, miR-185, and let-7a, but
increased expression of miR-31 in lung carcinoma tissues and can-
cer cell lines. Overexpression of miR-107 and miR-185 significantly
reduced A549 and H1299 cell proliferation. Both miRNAs signifi-
cantly increased the percentage of cancer cells in the G1 cell cycle
phase. Inhibition of miR-107 increased the proliferation of A549
lung cancer cells (Cheng et al., 2005). Overexpression of let-7a,
miR-107, and miR-126 suppresses lung cancer cell growth (Zhong
et al., 2010).
Let-7 is an important miRNA and is highly expressed in lung
tissue, as supported by in vitro and in vivo studies (Johnson et al.,
2005; Yanaihara et al., 2006). The tumor-suppressive let-7 family
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FIGURE 1 | miRNA biogenesis. MiRNAs are transcribed by RNA polymerase
II (Pol II) into long primary miRNA transcripts, which are cleaved in the
nucleus by the RNase III enzyme Drosha, resulting in a hairpin precursor form
called pre-miRNA. Pre-miRNA is exported from the nucleus to the cytoplasm
by exportin 5 and is further processed by the enzyme Dicer which produces a
transient miRNA duplex. Only one strand of the miRNA duplex (mature
miRNA) is incorporated into a large protein complex called RISC
(RNA-induced silencing complex).
targets well known oncogenes like Ras (Johnson et al., 2005), c-Myc
(Sampson et al., 2007), and HMGA2 (Lee and Dutta, 2007) which
are involved in lung cancer carcinogenesis. The let-7 family has a
tumor-suppressive role in NSCLC in animal models (Kumar et al.,
2008; Trang et al., 2010). It was demonstrated that 40% of lung
tumors and 60% of lung cancer cell lines have low expression lev-
els of let-7 (Takamizawa et al., 2004). In another study low let-7
expression levels were confirmed and could be correlated to high
RAS expression in lung tumor models (Johnson et al., 2005, 2007).
Together with further studies showing different miRNA expression
profiles (Fabbri et al., 2007; Navarro et al., 2009; Raponi et al., 2009;
Seike et al., 2009) seven miRNAs have frequently been found to
be downregulated in NSCLC: let-7, miR-29 family, miR-30a, miR-
124a, miR-126∗, miR-126, and miR-145 whereas six miRNAs are
higher expressed in NSCLC tissue based on these studies: miR-
17, miR-21, miR-106a, miR-182, miR-203, and miR-210. Own
data confirmed a significant downregulation of miR-29b in lung
adenocarcinoma compared to surrounding non-cancerous tissue
(Rothschild et al., 2012a).
Members of the miRNA-29 family (miR-29a, miR-29b, and
miR-29c) are known to be highly expressed in normal tissues
and downregulated in different types of cancer, including neurob-
lastoma, sarcoma, glioma, high-risk chronic lymphatic leukemia
(CLL), invasive breast cancer, cholangiocarcinoma, and lung can-
cer (Calin et al., 2005; Iorio et al., 2005; Yanaihara et al., 2006; Mott
et al., 2007; Wu et al., 2009; Xu et al., 2009). The three miR-29 iso-
forms are arranged in two clusters: miR-29b1/miR-29a located on
chromosome 7q32 and miR-29b2/miR-29c located on chromo-
some 1q32. miR-29a has been shown to reduce invasiveness and
proliferation of human carcinoma cell lines (Muniyappa et al.,
2009). In lung cancer the miR-29 family members also target DNA
methyltransferases (DNMT3A and DNMT3B), and can thereby
restore patterns of DNA methylation and expression of silenced
tumor suppressor genes (Fabbri et al., 2007). In our own study we
demonstrated direct binding or miR-29b to inhibitor of differen-
tiation 1 (ID1) (Rothschild et al., 2012a). Anti-miR-29b enhanced
ID1 mRNA and protein levels, and significantly increased lung
cancer cell migration and invasion, a hallmark of the Src-ID1
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pathway. miR-29b suppressed the level of ID1 and significantly
reduced migration and invasion.
Hypoxia-inducible factor-1α (HIF-1α) is considered a key reg-
ulator of tumor angiogenesis (Semenza, 2010). The polycistronic
cluster miR-17-92 consisting of six miRNAs (miR-17, miR-18a,
miR-19a, miR-19b-1, miR-20a, miR-92a-1) is involved in embry-
onal lung development (Lu et al., 2007). Mice deficient for miR-
17-92 die shortly after birth with lung hypoplasia and a ventricular
septal defect (Ventura et al., 2008). This miRNA cluster is overex-
pressed in several lung cancer cell lines, preferentially in SCLC and
the overexpression is associated with increased cell proliferation
(Hayashita et al., 2005). The inhibition of miR-17-92 by antisense
oligonucleotides can induce apoptosis in overexpressing cell lines
(Matsubara et al., 2007). miR-17-92 targets HIF-1α which might
be the key mechanism of action in lung cancer cell proliferation
(Taguchi et al., 2008). Moreover, miR-519c binds to the HIF-1α
3′UTR and thereby reduces tumor angiogenesis (Cha et al., 2010).
Retinoblastoma 1 (Rb1) was the first identified tumor sup-
pressor. Overexpression of miR-192 inhibited cell proliferation in
A549, H460, and 95D lung cancer cells by decreasing Rb1 mRNA
and protein expression (Feng et al., 2011). The same effect was
demonstrated in a nude mouse model.
Epidermal growth factor receptor signaling has been shown
to play an important role in cell migration and invasion (Pren-
zel et al., 2001). miR-125a-5p is regulating several downstream
genes involved in EGFR signaling (Wang et al., 2009). Inhibition
of miR-125a-5p significantly enhanced cell migration and inva-
sion, suggesting that miR-125a-5p is negatively correlated with
lung cancer invasion and metastasis.
Further miRNAs that have been described to have tumor-
suppressive function in lung cancer are miR-93 (Du et al., 2009),
miR-98 (Du et al., 2009), miR-101 (Zhang et al., 2011), miR-182
(Sun et al., 2010), miR-197 (Du et al., 2009), miR-212 (Incoronato
et al., 2010), miR-451 (Wang et al., 2011).
Recently, it has been shown that miRNAs are also present in
body fluids, shuttled by so called exosomes, which are secreted
both by normal and tumor cells. Two miRNAs (miR-23 and miR-
225) are expressed at higher levels in the circulating exosomes of
NSCLC patients compared to healthy donors (Chen et al., 2008).
There seems to be a correlation between the expression of miR-
NAs in tumor tissues and in the blood suggesting that the tumor
releases circulating miRNAs inside exosome particles (Rabinowits
et al., 2009). A recent publication identified specific miRNAs (e.g.,
miR-21 and miR-29a) in exosome of lung cancer patients able to
bind and activate Toll-like receptors (TLR) in cancer surround-
ing immune cells (Fabbri et al., 2012). By activating TLRs, these
miRNAs trigger the NF-kappaB pathway which ultimately leads
to an increased production of interleukin-6 (IL-6) and tumor
necrosis factor-alpha (TNF-alpha) by the immune cells, leading
to increased tumor growth and metastatic potential. This study
describes a novel mechanism of action of miRNAs and support the
role of cancer-released exosomes in lung cancer carcinogenesis.
In general, the current literature suggests that miRNAs are
involved in lung cancer carcinogenesis by different mecha-
nisms. They might act directly by targeting oncogenes or tumor
suppressor genes and regulate their expression or by influenc-
ing their epigenetic regulation within the tumor. As a novel
mechanism, miRNAs also affect lung carcinogenesis by triggering
a TLR-mediated oncogenic inflammatory response.
MicroRNA AS DIAGNOSTIC MARKERS OF LUNG CANCER
Since there is no validated population-based screening proce-
dure available, most patients with lung cancer are diagnosed at
advanced stages. Recently a large trial showed that low-dose heli-
cal CT screening in an older, high-risk population reduced lung
cancer mortality by 20% (Aberle et al., 2011a,b). However there
is a high number of false positive findings in CT scans (Aberle
et al., 2011a; Barba et al., 2011). Therefore, development of a
reliable and non-invasive confirmatory test would reduce over-
diagnosis. Interestingly, miRNA expression levels show apparent
differences following exposure to cigarette smoking (Izzotti et al.,
2009). Therefore changes in miRNA expression might be a reliable
tool for cancer early detection in smokers. Xie et al. (2010) found
that miR-21 expression in the sputum specimens was significantly
higher in cancer patients compared with healthy controls. Fur-
ther studies have shown that increased miR-21 expression resulted
in 70% sensitivity and 100% specificity in the diagnosis of lung
cancer by sputum cytology (Wang et al., 2012). Therefore, investi-
gating miRNA expression levels in the sputum might be a potential
non-invasive approach for early lung cancer detection.
Yanaihara et al. (2006) studied miRNA expression profiles in
lung cancer tissues and normal adjacent tissue. They identified a
unique miRNA profile allowing discriminating lung cancers from
non-cancerous lung tissues. Furthermore they describe a signature
that distinguishes histological subtypes of NSCLC. Some of the
miRNAs (e.g., miR-21, miR-155, and members of the miR-17-92
cluster) were common to the two studies, and have been found to
be upregulated in other types of cancer. Shen et al. (2011) identified
12 miRNAs aberrantly expressed in early-stage NSCLC. Four of
them (miR-21, miR-126, miR-210, and miR-486-5p) yielded 86%
sensitivity and 97% specificity in distinguishing NSCLC patients
from healthy controls. Furthermore, these miRNAs had higher
sensitivity (92%) in diagnosing lung adenocarcinoma compared
with squamous cell carcinomas (82%) (p< 0.05). In a recent study
miRNA expression in tumor and non-cancerous tissue pairs col-
lected from stage I-III lung squamous cell carcinoma patients
treated with neoadjuvant chemotherapy or radiotherapy were
analyzed (Tan et al., 2011). Five miRNAs (miR-30a, miR-140-3p,
miR-182, miR-210, and miR-486-5p) were identified to distinguish
invasive lung cancer from non-cancerous lung tissue. The classifier
had an accuracy of 94.1% in a training cohort (34 patients) and
96.2% in a test cohort (26 patients). Yu et al. (2010) found that
the combined overexpression of miR-21, miR-200b, miR-375, and
miR-486 in surgical tissues and sputum were biomarkers in the
prediction of lung adenocarcinoma from normal controls with
81% sensitivity and 92% specificity. The results have been vali-
dated in 64 lung cancer patients and 58 cancer-free participants.
The detection of miR-205, miR-210, and miR-708 in sputum was
highly sensitive (73%) and specific (96%) in diagnosing lung
cancer (Xing et al., 2010).
Compared with normal lung tissues, the top 10 deregulated
miRNAs in lung tumors that were appropriate for discriminat-
ing CT-detected lung cancer from normal lung tissue were let-7,
miR-21, miR-200b, miR-210, miR-219-1, miR-324, which were
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all upregulated, and miR-30a, miR-126, miR-451, and miR-486,
which were all downregulated (Boeri et al., 2011).
The histopathological subclassification of NSCLC into the two
large groups adenocarcinoma and squamous cell carcinoma has
gained interest during the last years because adenocarcinoma
histology in stage IV NSCLC is predictive for treatment with
pemetrexed (Scagliotti et al., 2009). Two miRNAs (miR-21, miR-
205) were reported to accurately distinguish adenocarcinoma from
squamous cell carcinoma subtype (Lebanony et al., 2009).
Moreover, different miRNA expression profiles were also
described between primary lung tumors and metastases. Overex-
pression of miR-182 was found in primary lung cancers, whereas
miR-126 was highly expressed in metastatic tumors (Barshack
et al., 2010).
In conclusion, these results suggest that miRNA signatures can
help to differentiate lung cancer tissue from non-cancerous lung
tissue. Furthermore, there are specific miRNAs associated with
early lung cancer development which could be measured in spu-
tum specimens and might support early lung cancer diagnosis.
Other miRNAs can help to distinguish between histopatholog-
ical subtypes of NSCLC or between lung primary tumors and
metastases.
MicroRNAs AS PROGNOSTIC BIOMARKERS OF LUNG
CANCER
At least two studies demonstrated the prognostic role of let-7 in
patients with NSCLC. Takamizawa et al. (2004) investigated 159
patients with stage I-III NSCLC and showed that low expression
of let-7 was associated with a shorter postoperative survival. This
finding was confirmed by Yanaihara et al. (2006) showing that
overexpression of the precursor of miR-155 and the downregula-
tion of let-7a-2 correlated with poor survival in NSCLC patients.
This result was confirmed in a further study (Chin et al., 2008).
In a study by Yu et al. (2008) let-7a was part of a signature of
five miRNAs (let-7a, miR-137, miR-182∗, miR-221, miR-372) that
were prognostic predictors. Reduced expression of miR-146b was
found to be associated with a reduced overall survival in patients
undergoing radical surgery for squamous cell carcinoma of the
lung (Raponi et al., 2009). Another study in stage I-III squamous
cell carcinoma showed a negative prognostic impact of high miR-
31 expression (Tan et al., 2011). In male smokers with stage I-IIIA
squamous cell of the lung, Landi et al. (2010) identified a signature
of five downregulated miRNAs (let-7e, miR-25, miR-34a, miR-
34c-5p, miR-191) predicting for poor outcome. miR-328 might
be a marker for patients at higher risk for brain metastases as this
miRNA has been found to be differentially expressed in patients
with and without brain metastases of NSCLC (Arora et al., 2011).
Lower expression of miR-34a in tumor tissues was associated with
a high recurrent risk (Gallardo et al., 2009). High miR-21 and low
miR-181 expression levels predicted poor survival independent
of TNM staging (Gao et al., 2010). In another study overexpres-
sion of miR-429 was associated with shorter disease-free survival
and downregulation of miR-486-5p in plasma predicted for poor
outcome (Donnem et al., 2011).
The role of adjuvant chemotherapy in surgically resected stage
I NSCLC is controversial (Besse and Le Chevalier, 2012). Reli-
able biomarkers predicting the risk of relapse are needed to
identify patients most likely to benefit from adjuvant chemother-
apy. Patnaik et al. (2010) demonstrated that miRNAs can pre-
dict lung cancer recurrence with an accuracy of 83%. Lu et al.
(2012) reported on 527 stage I NSCLC patients investigated for
miRNA expression levels. Two miRNA signatures were associ-
ated with relapse-free survival. The first contained 34 miRNAs
derived from 357 patients whereas the second was based on 27
miRNAs from adenocarcinoma histologies. Both signatures were
validated in an independent data set with 170 stage I NSCLC
patients.
In the largest cohort of NSCLC patients investigating the prog-
nostic and predictive value of miRNA signatures 639 patients
with radically resected stage I-III NSCLC randomized to adjuvant
cisplatin-based chemotherapy or follow-up [IALT trial (Arria-
gada et al., 2004)] were included (Voortman et al., 2010). miRNA
expression levels in the tumor tissue were analyzed using quanti-
tative real-time PCR (qRT-PCR). Only low expression of miR-21
was associated with shorter survival time. None of the investigated
miRNAs nor any of the tested signatures was of predictive value
for adjuvant chemotherapy. Hu et al. (2010) described a signa-
ture of circulating miRNAs (miR-1, miR-30d, miR-486, miR-499)
associated with the outcome in 303 surgically resected stage I-IIIA
NSCLC patients treated with adjuvant chemotherapy.
In our own study, we extracted total RNA from tumors and
matched non-cancerous lung tissue from 23 cases with a patholog-
ical diagnosis of lung adenocarcinoma (Rothschild et al., 2012a).
miRNA expression levels were determined using qRT-PCR. In
19 (83%) of the cases, miR-29b was downregulated in tumor
compared with matched lung. Using the median tumor level as
cut-off value, tumor miR-29b expression significantly correlated
with event-free (p= 0.003) and overall survival (p= 0.039). In
another study we extracted total RNA from 18 tissue samples of
lung adenocarcinoma and also from non-cancerous tissue from
the same patients (Rothschild et al., 2012b). In 15/18 (83%) of
analyzed adenocarcinoma samples, miR-381 was downregulated
in tumor compared with normal lung tissue. Overall miR-381
expression was significantly lower in adenocarcinomas than in
matched normal lung tissue (Mann–Whitney U test, p= 0.003).
Using the median tumor level as cut-off, tumor miR-381 expres-
sion significantly correlated with event-free survival (p= 0.003)
and overall survival (p= 0.02).
In conclusion, several miRNAs show tissue specific expression
levels and can be correlated with patient outcome.
MicroRNA AS PREDICTIVE MARKERS IN LUNG CANCER
As discussed in the section on miRNA as prognostic markers, the
largest clinical trial evaluating the role of miRNA signatures in
NSCLC did not show any of the examined miRNAs to be of predic-
tive value (Voortman et al., 2010). Nevertheless, several preclinical
studies as well as miRNA expression analyses from clinical trials
showed that certain miRNAs might be of predictive value and do
influence the sensitivity of lung cancer cells to chemotherapeutic
or targeted agents as well as to irradiation.
In our own study we raised the hypothesis that miR-29b is a
potential predictive marker for SRC TKIs due to the fact that inhi-
bition of miR-29b diminished the effects of SRC tyrosine kinase
inhibition (Rothschild et al., 2012a).
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miR-17-92, miR-221, and miR-222 have been shown to sensi-
tize lung cancer cells to cytotoxic agents (Hayashita et al., 2005;
Matsubara et al., 2007; Garofalo et al., 2008). Galluzzi et al. (2010)
demonstrated that miR-181a and miR-630 modulate the sensitiv-
ity of lung cancer cell lines toward cis-diamminedichloroplatinum
(cis-DDP). pre-miR-630 diminished the sensitivity of A549 cells
in response to DDP by inducing cancer cell arrest in G0-G1
and increasing the cell cycle inhibitor p27kip1. Ectopic expres-
sion of miR-451 on the other hand sensitized A549 cells to
DDP possibly by increasing DDP-induced apoptosis (Bian et al.,
2011).
The description of oncogenic mutations (e.g., EGFR muta-
tions) and the introduction of new therapeutics directly targeting
these molecular changes (e.g., EGFR TKIs) have changed the
therapeutic strategies in lung cancer treatment. Therefore, higher
interest in understanding sensitivity and resistance mechanisms
toward these new therapeutic approaches is a consequence of
this development. Higher expression of miR-126 enhanced cyto-
toxicity induced by gefitinib in lung cancer cells (Zhong et al.,
2010). EGFR is directly targeted by miR-128b and miR-128b loss-
of-heterozygosity (LOH), which is frequently found in NSCLC,
is a direct regulator of EGFR, correlates with clinical response
and survival following gefitinib therapy (Weiss et al., 2008). Also,
miR-21 was shown to enhance the therapeutic effects of EGFR
TKIs in lung cancer cell lines (Seike et al., 2009). miR-7 has
been described to target EGFR, AKT, and ERK and therefore sup-
pressing EGFR pathway signaling (Webster et al., 2009). Ectopic
expression of miR-7 was able to overcome EGFR TKI resistance in
lung cancer cell lines (Rai et al., 2011). Another study described
that restoration of tumor suppressor miR-145 inhibits cancer
cell growth in EGFR mutant lung adenocarcinoma (Cho et al.,
2009).
TRAIL (Apo2L/tumor necrosis factor-related apoptosis-
inducing ligand) is a member of the TNF family that can induce
apoptosis in several types of cancer, including lung cancer (Schae-
fer et al., 2007). miR-221 and miR-222 silence PTEN and TIMP3
tumor suppressors and therefore lead to resistance of lung cancer
cells toward TRAIL (Garofalo et al., 2009).
The role of miRNA expression related to irradiation has been
investigated by several groups. A549 cells, which contain lower
let-7 levels and higher activated RAS had significant changes in
miRNAs as early as 2 h after irradiation (Weidhaas et al., 2007).
Inhibition of let-7b caused significant protection from radiation
(Galluzzi et al., 2010). On the other hand, overexpression of let-7g
protected A549 cells from radiation, whereas inhibition of let-7g
increased radiosensitization in lung cancer cells (Galluzzi et al.,
2010).
In conclusion, despite a large negative study on the predic-
tive role of miRNAs signatures in NSCLC further studies are
warranted on the basis of several preclinical data. As shown in
various studies miRNA can modulate the response of lung can-
cer cells to EGFR TKIs by interacting with the respective signaling
pathway. Confirmation of their predictive role in larger clinical
trials is needed.
CONCLUSION
Since their discovery in the 1990s miRNAs have increasingly been
recognized as key player in carcinogenesis and cancer progression,
but also as potential diagnostic markers and biomarkers. In this
overview more insights in the involvement of miRNAs in lung car-
cinogenesis as well as in their role as diagnostic, prognostic, and
predictive biomarkers have been summarized. The current evi-
dence on the prognostic and predictive role of miRNAs is at least
partially inconsistent. Therefore, prospective trials evaluating the
role of miRNAs described to have prognostic or predictive impact
in small retrospective analysis should be planned. For this, stan-
dardized protocols for the isolation and the analysis of expression
levels of miRNAs are needed.
For the future, miRNAs from body fluids, especially the blood
plasma might be the center of attention. As discussed, numer-
ous studies have identified aberrant miRNA expression pro-
files in lung cancer. Therefore, miRNAs can potentially be used
as biomarkers in the diagnosis and classification of lung can-
cer. Moreover, miRNA expression levels in blood plasma may
be used as a non-invasive confirmatory screening test com-
plementary to the low-dose helical CT screening in the near
future.
Another interesting research field is the use of miRNAs as ther-
apeutic agents. The miRNA replacement or the anti-miRNAs will
possibly become a new strategy for lung cancer therapy. At the
moment several challenges have to be resolved before miRNAs
could be investigated in clinical trials. One of the main prob-
lems is to find a suitable non-toxic delivery system capable of
selectively transporting miRNA-based therapeutics to the tumor
site. As discussed in the introduction, one single miRNA is able
to target more than 100 mRNAs. It is therefore highly ques-
tionable if miRNAs as therapeutic tools could be of sufficient
specificity.
In conclusion, current knowledge on miRNAs in lung cancer
has extended our understanding of lung cancer carcinogenesis
and provides health care professionals with a new and innova-
tive cancer biomarker. Beside preclinical research, there are several
clinical trials evaluating the role of miRNAs as prognostic and/or
predictive biomarkers ongoing.
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